Je Dois Lavoir 365 SKINNY Capsules Recall: Undeclared Sibutramine Risk
FDA recalls Je Dois Lavoir's 365 SKINNY High Intensity Capsules due to undeclared sibutramine, a withdrawn drug with safety concerns. Consumers should stop using affected lots.
Stop using this now
Marketed Without an Approved NDA/ANDA: FDA analysis found the product to be tainted with undeclared sibutramine, a previously approved drug that was withdrawn from the US market due to safety concerns.
Contact the company
What happened, in plain English
Je Dois Lavoir is recalling 365 SKINNY High Intensity Capsules (600 mg, 30-count) because they contain undeclared sibutramine, a drug previously approved but withdrawn from the US market due to safety issues. This poses a risk of serious health effects if taken. Read more at govinfonow.com/recall/35993-je-dois-lavoir-365-skinny-capsules-recall-undeclared-sibutramine-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/35993-je-dois-lavoir-365-skinny-capsules-recall-undeclared-sibutramine-risk · Updated August 18, 2026 · FDA enforcement record: FDA #D-0631-2022
Cite this page
“Je Dois Lavoir 365 SKINNY Capsules Recall: Undeclared Sibutramine Risk.” GovInfoNow, updated August 18, 2026. https://govinfonow.com/recall/35993-je-dois-lavoir-365-skinny-capsules-recall-undeclared-sibutramine-risk. Based on FDA recall #D-0631-2022 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0631-2022%22&limit=1).
Why it’s dangerous
The capsules contain undeclared sibutramine, a drug that was approved in the US but later withdrawn because it caused serious health risks. This means the product could lead to adverse effects like heart problems or other serious health issues if taken.
Who’s affected
Anyone who owns or uses the recalled 365 SKINNY High Intensity Capsules (600 mg, 30-count) from Je Dois Lavoir. People taking these capsules for weight loss are most at risk due to the undeclared sibutramine.
How to tell if you have this one
Check for the product name '365 SKINNY High Intensity Capsules', 600 mg, 30-count bottle, and the lot number 102-26 (expired December 2022).
- Brand
Je Dois Lavoir- Category
Drug
What to do — step by step
Stop Using Now
Immediately stop taking the recalled capsules as they contain undeclared sibutramine, a drug withdrawn from the US market due to safety concerns.
Where it went and when
Where it was distributed
Distributed nationwide, and outside the U.S.
FDA distribution: “Sold online via website nationwide in the USA and Canada.” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide, and outside the U.S.
Recall timeline
FDA terminated this recall 21 months after the firm started it.
- Firm started the recall
- FDA classified it Class I
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0631-2022 (August 2, 2021) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0631-2022 to see it in context.
- Plain-language summary written by qwen3:4b on August 18, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.